COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 6 for:    fisetin, mayo
Previous Study | Return to List | Next Study

COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04476953
Recruitment Status : Enrolling by invitation
First Posted : July 20, 2020
Last Update Posted : August 13, 2020
Information provided by (Responsible Party):
James L. Kirkland, Mayo Clinic

Brief Summary:
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Placebo Drug: Fisetin Phase 2

Detailed Description:
To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/ critical proven COVID-19 (CoV) infection (WHO/NIH Baseline Severity Classification) in non-ICU hospitalized patients and to evaluate the safety and tolerability of Fisetin in this patient population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults
Actual Study Start Date : August 3, 2020
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Arm Intervention/treatment
Experimental: Treatment Group
Subjects will receive treatment drug Fisetin
Drug: Fisetin
~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
Other Name: 3,3',4',7-tetrahydroxyflavone

Placebo Comparator: Placebo Group
Subjects will receive placebo
Drug: Placebo
Placebo looks exactly like the study drug, but it contains no active ingredient.

Primary Outcome Measures :
  1. Serious Adverse Events [ Time Frame: 6 months ]
    Number of participants to experience serious adverse events and hypersensitivity reactions.

  2. Change in oxygenation status [ Time Frame: baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6 ]
    change in oxygenation levels as measured by S/F ratio (SPO2/FiO2)

Secondary Outcome Measures :
  1. COVID-19 Severity Category [ Time Frame: 6 months ]
    Number of participants to progress to severe or critical classification measure by the WHO/ NIH Baseline Severity Classification criteria descriptions of SARS-CoV-2 infection without symptoms, Mild COVID-19 (CoV), Moderate CoV, Severe CoV and Critical CoV

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria - Patients must meet all of the following inclusion criteria to be enrolled in this study.

  1. Men or women 60 years of age or older


    Age 18 - 59 years WITH at least one of the following comorbidities:

    • BMI greater than or equal to 35
    • Diabetes
    • Asthma/ Chronic Obstructive Pulmonary Disease (COPD)
    • Previous Myocardial Infarction
    • Previous Stroke/ Cerebrovascular Accident (CVA)
    • Hypertension/ Atherosclerosis/ Peripheral Vascular Disease
    • Smoking and/or vaping
    • Other conditions associated with senescent cell accumulation (i.e. previous chemotherapy or radiation)
  2. SpO2 greater than or equal to 85% on room air within previous 72 hours AND 2 L of oxygen or less by nasal cannula (or on room air) at time of enrollment.
  3. Willing and able to provide written informed consent or have a legally authorized representative (LAR) who will provide informed consent.
  4. SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic's Central Laboratory within 72 hours before randomization.

Exclusion Criteria - Patients who meet any of the following exclusion criteria are not to be enrolled in this study.

General Exclusion Criteria

  1. Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial.
  2. Mechanically-ventilated (including V-V ECMO or V-A ECMO).
  3. Severe or critical CoV (WHO/ NIH Categorization; Table 3) at time of randomization.
  4. Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization.
  5. WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration. (Section 5.10)
  6. Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration. (Section 5.10)

    Laboratory Exclusion Criteria

  7. Total bilirubin >3X upper limit of normal or as per clinical judgment.
  8. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) >4x the upper limits of normal or as per clinical judgment.
  9. Hemoglobin <7 g/dL; white blood cell count ≤ 2,000/mm3 (< or = 2.0 x 109/L) or > or = 20,000/mm3 (> or = 20 x 109/L); platelet count < or = 60,000/µL (< or = 60 x 109/L); absolute neutrophil count < or = 1 x 109/L; lymphocyte count <0.5 x 109/L at screening or as per clinical judgment.
  10. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine, immunological, or hepatic disorder.
  11. eGFR <25 ml/ min/ 1.73 m2 or as per clinical judgment.
  12. Plasma glucose >300 or as per clinical judgment.
  13. Cystatin C >3x upper limit of normal or as per clinical judgment.

    Clinical History Exclusion Criteria

  14. Human immunodeficiency virus infection.
  15. Known active hepatitis B or C infection.
  16. Invasive fungal infection.
  17. Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites.
  18. New/active invasive cancer except non-melanoma skin cancers.

    Medication Exclusion Criteria (See Appendices 1-3 for additional information)

  19. Known hypersensitivity or allergy to Fisetin.
  20. Patients currently using medications which utilize CYP450 2C9 for metabolism. These medications include: Fosphenytoin, Phenytoin, Warfarin, Glimepiride, Diclofenac, Bosentan, and Glyburide. Patients taking Losartan may participate if Losartan can be held until study Day 3 and the patient is otherwise eligible.
  21. Patients currently using medications which utilize CYP2C9, CYP2C19, CYP1A2, OATP1B1. These medications include: Olanzapine, Clozapine, Theophylline, Tizanidine, Warfarin, Rameltoen, Tacrine, Duloxetine, Mexiletine, Riluzole, and Atomoxetine. Patients taking Colchicine may participate if Colchicine can be reduced by half until study Day 3 and the patient is otherwise eligible. Patients taking Venlafaxine may participate if Venlafaxine can be held until study Day 3 and the patient is otherwise eligible.
  22. Patients currently using medications which are strong inhibitors of CYP3A4. These medications include: Atazanavir, Ceritinib, Clarithromycin, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mefipristone, Nefazodone, Nelfinavir, Ombitasivir-paritaprevir-ritonivir, Ombitasivir-paritaprevir-ritonivir-plus dasabuvir, Posaconazole, Saquinavir, Telithromycin, Tucatinib, and Voriconazole.
  23. Patients currently using antifungals. If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are subtherapeutic or therapeutic.
  24. Patients currently using any of the following medications (unless willing to discontinue the medication during the study):

    • Cardiac: digoxin, flecainide, amiodarone
    • Psychiatric: lithium, thioridazine
    • Neurologic: carbamazepine, phenobarbital
    • Antimicrobial/fungal: aminoglycosides (e.g. amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomysin, streptomycin, tobramycin), rifampin
    • Anticoagulants/ Antiplatelets: warfarin
    • Others: methotrexate, nitroglycerin, St. John's wort, tyrosine kinase inhibitors, tacrine, diclofenac
  25. Participation in other clinical trials involving treatment for COVID-19. Note that institutional standard of care treatment of COVID-19 including glucocorticoids, hydroxychloroquine, azithromycin and/or remdesivir are not excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04476953

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: James L Kirkland Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: James L. Kirkland, Principal Investigator, Mayo Clinic Identifier: NCT04476953    
Other Study ID Numbers: 20-003936
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: August 13, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No